Johnson & Johnson (NYSE:JNJ) Shares Sold by Karp Capital Management Corp

Karp Capital Management Corp cut its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 4.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,459 shares of the company’s stock after selling 165 shares during the period. Karp Capital Management Corp’s holdings in Johnson & Johnson were worth $613,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Family CFO Inc acquired a new position in Johnson & Johnson during the fourth quarter worth $26,000. Steward Financial Group LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth $34,000. Jackson Wealth Management LLC increased its holdings in Johnson & Johnson by 1.7% in the third quarter. Jackson Wealth Management LLC now owns 16,959 shares of the company’s stock valued at $40,000 after buying an additional 277 shares during the last quarter. Advocacy Wealth Management Services LLC increased its holdings in Johnson & Johnson by 41.4% in the first quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock valued at $41,000 after buying an additional 67 shares during the last quarter. Finally, Iron Horse Wealth Management LLC grew its holdings in shares of Johnson & Johnson by 29.9% during the fourth quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company’s stock worth $45,000 after purchasing an additional 61 shares during the last quarter. Hedge funds and other institutional investors own 68.78% of the company’s stock.

Several equities research analysts have recently weighed in on the stock. Citigroup decreased their target price on shares of Johnson & Johnson from $210.00 to $205.00 in a research note on Tuesday, May 17th. Credit Suisse Group raised their price objective on shares of Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. Raymond James raised their price objective on shares of Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. The Goldman Sachs Group raised their price objective on shares of Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a research report on Tuesday, April 12th. Finally, Morgan Stanley dropped their target price on shares of Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating for the company in a report on Wednesday, April 6th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $190.50.

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at $2,785,140. The disclosure for this sale can be found here. Insiders sold a total of 78,161 shares of company stock valued at $13,895,302 over the last ninety days. 0.35% of the stock is owned by corporate insiders.

Shares of JNJ opened at $175.74 on Thursday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14. The firm has a 50 day simple moving average of $177.66 and a 200-day simple moving average of $173.09. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69. The stock has a market cap of $462.44 billion, a price-to-earnings ratio of 23.68, a price-to-earnings-growth ratio of 3.35 and a beta of 0.66.

Johnson & Johnson (NYSE:JNJGet Rating) last released its earnings results on Tuesday, April 19th. The company reported $2.67 EPS for the quarter, topping the consensus estimate of $2.60 by $0.07. The firm had revenue of $23.43 billion during the quarter, compared to analysts’ expectations of $23.62 billion. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. Johnson & Johnson’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the previous year, the company earned $2.59 EPS. On average, equities analysts expect that Johnson & Johnson will post 10.23 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th were paid a $1.13 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.06. This represents a $4.52 annualized dividend and a yield of 2.57%. The ex-dividend date of this dividend was Monday, May 23rd. Johnson & Johnson’s payout ratio is presently 60.92%.

Johnson & Johnson Company Profile (Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.